The updates to the guidelines reflect recent advances, including recommended immunotherapies and changes in tumor staging.
The updated version incorporates biologic factors to refine and improve the prognostic stratification of patients with breast cancer.
Among the updates are expanded treatment options, including a recently approved immunotherapy regimen for locally advanced or metastatic disease.